Normandie Univ, UNIROUEN, Inserm U1245, IRON Group, Normandy Centre for Genomic and Personalized Medicine, Rouen University Hospital, F-76031, Rouen, France.
AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F-75013, Paris, France.
Curr Neurol Neurosci Rep. 2018 Mar 9;18(3):13. doi: 10.1007/s11910-018-0820-z.
Personalized medicine is a challenge to improve survival and quality of life of patients suffering from primary malignant brain tumor. Molecular biology is integrated in initial diagnosis and relapse, and, in the nearest future, over treatment schedule and monitoring. Liquid biopsy is a minimally invasive way to obtain tumor material.
Over the past years, three fluids have been explored to provide tumor information in primary malignant brain tumor: blood, cerebrospinal fluid, and vitreous liquid. Different tumor components were identified: (1) circulating tumor cells, (2) circulating tumor DNA, (3) RNA and non-coding miRNA, and (4) extracellular vesicles. The performance of the liquid biopsy depends on the tumor type and on the method of detection. Liquid biopsy could be a valuable tool to improve patient care in primary malignant brain tumor. Improvement of its sensitivity is the major challenge to generalize its use in daily practice.
个性化医疗是改善原发性脑恶性肿瘤患者生存和生活质量的挑战。分子生物学整合在初始诊断和复发中，在不久的将来，还将整合在治疗方案和监测中。液体活检是获取肿瘤组织的一种微创方法。
在过去的几年中，已经探索了三种液体来提供原发性脑恶性肿瘤的肿瘤信息：血液、脑脊液和玻璃体液体。不同的肿瘤成分被识别：（1）循环肿瘤细胞，（2）循环肿瘤 DNA，（3）RNA 和非编码 miRNA，（4）细胞外囊泡。液体活检的性能取决于肿瘤类型和检测方法。液体活检可能是改善原发性脑恶性肿瘤患者护理的有价值工具。提高其敏感性是将其在日常实践中广泛应用的主要挑战。
